| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
101,000,000 |
| Market
Cap: |
790.83(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.7528 - $16.06 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 9.5 |
| Insider 3/6 Months : 10.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Co.'s primary product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
230,000 |
330,000 |
350,000 |
| Total Buy Value |
$0 |
$310,500 |
$455,990 |
$472,790 |
| Total People Bought |
0 |
2 |
3 |
4 |
| Total Buy Transactions |
0 |
2 |
3 |
4 |
| Total Shares Sold |
0 |
0 |
6,201 |
140,082 |
| Total Sell Value |
$0 |
$0 |
$9,429 |
$134,803 |
| Total People Sold |
0 |
0 |
1 |
5 |
| Total Sell Transactions |
0 |
0 |
1 |
9 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Soparkar Peter |
See Remarks section |
• – – |
2021-12-08 |
4 |
B |
$1.91 |
$47,750 |
D/D |
25,000 |
258,631 |
2.74 |
-39% |
|
| Fischer Laurent |
CEO, President and Director |
• • – |
2021-12-08 |
4 |
B |
$1.79 |
$19,112 |
D/D |
10,677 |
723,139 |
2.81 |
-39% |
|
| Dsouza Rupert |
Chief Financial OfficerOfficer |
• – – |
2021-12-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
850 |
|
-37% |
|
| Scopa James Paul |
Director |
– • – |
2021-11-15 |
4 |
S |
$2.18 |
$109,000 |
I/I |
(50,000) |
3,334 |
|
36% |
|
| Clark Julie |
Chief Medical Officer |
• – – |
2021-09-30 |
4 |
S |
$2.17 |
$10,342 |
D/D |
(4,766) |
164,723 |
|
31% |
|
| Riley Brigit |
Chief Scientific OfficerOffice |
• – – |
2021-09-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
120,000 |
|
-37% |
|
| Fischer Laurent |
CEO, President and Director |
• • – |
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
680,000 |
706,292 |
|
- |
|
| Clark Julie |
Chief Medical Officer |
• – – |
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
120,000 |
169,489 |
|
- |
|
| Thedinga Angela |
Chief Technology Officer |
• – – |
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
150,000 |
|
- |
|
| Soparkar Peter |
See Remarks section |
• – – |
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
220,000 |
230,692 |
|
- |
|
| Clark Julie |
Chief Medical OfficerOfficer |
• – – |
2021-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
49,489 |
|
-41% |
|
| Graham Dawn |
Director |
– • – |
2021-03-31 |
4 |
B |
$10.02 |
$200,338 |
D/D |
20,000 |
20,000 |
2.39 |
-75% |
|
| Machado Clarence Patrick |
Director |
– • – |
2021-03-24 |
4 |
B |
$9.92 |
$99,196 |
D/D |
10,000 |
88,182 |
2.39 |
-75% |
|
| Fischer Laurent |
CEO and Director |
• • – |
2021-03-24 |
4 |
B |
$9.88 |
$98,780 |
D/D |
10,000 |
26,292 |
2.81 |
-75% |
|
| Patterson Leone D |
President and CFO |
• – – |
2021-02-09 |
4 |
S |
$14.10 |
$176,718 |
D/D |
(12,533) |
97,955 |
|
74% |
|
| Fischer Laurent |
CEO and Director |
• • – |
2021-01-15 |
4 |
B |
$11.53 |
$99,191 |
D/D |
8,600 |
16,292 |
2.81 |
-69% |
|
| Machado Clarence Patrick |
Director |
– • – |
2021-01-15 |
4 |
B |
$11.52 |
$115,174 |
D/D |
10,000 |
78,182 |
2.39 |
-69% |
|
| Woiwode Thomas |
Director |
– • – |
2020-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
12,783 |
18,822 |
|
- |
|
| Fischer Laurent |
CEO and Director |
• • – |
2020-08-17 |
4 |
B |
$13.00 |
$99,996 |
D/D |
7,692 |
7,692 |
2.81 |
-13% |
|
| Soparkar Peter |
Chief Legal Officer |
• – – |
2020-08-17 |
4 |
B |
$13.00 |
$99,996 |
D/D |
7,692 |
10,692 |
2.74 |
-13% |
|
| Gasmi Mehdi |
Director |
– • – |
2020-07-20 |
4 |
AS |
$17.60 |
$87,978 |
D/D |
(5,000) |
274,442 |
|
-22% |
|
| Gasmi Mehdi |
Director |
– • – |
2020-07-20 |
4 |
OE |
$4.80 |
$24,000 |
D/D |
5,000 |
279,442 |
|
- |
|
| Gasmi Mehdi |
Director |
– • – |
2020-06-22 |
4 |
AS |
$25.06 |
$591,617 |
D/D |
(23,605) |
274,442 |
|
-56% |
|
| Gasmi Mehdi |
Director |
– • – |
2020-06-22 |
4 |
OE |
$4.80 |
$113,304 |
D/D |
23,605 |
298,047 |
|
- |
|
| Gasmi Mehdi |
Director |
– • – |
2020-06-18 |
4 |
AS |
$25.01 |
$278,329 |
D/D |
(11,127) |
274,442 |
|
-54% |
|
266 Records found
|
|
Page 2 of 11 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.07 (0.89%) 
